ToxStrategies Acquires Clintrex Research Corporation

Renovus Capital Partners Majority Investment in ToxStrategies

January 24, 2023

Healthcare Services

Renovus Capital Partners made a majority investment in ToxStrategies, a multidisciplinary scientific consulting firm specializing in toxicology, epidemiology, exposure sciences and regulatory compliance. Five Points Capital provided debt and equity co-investment to support the transaction; terms were not disclosed and the deal was described as a recapitalization to support growth and expand services, staff and geographic reach.

ToxStrategies Acquires Suttons Creek

August 13, 2024

Healthcare Services

ToxStrategies, a Renovus Capital Partners portfolio company, has acquired Suttons Creek to expand its combination-product development and regulatory consulting capabilities. Brookside Capital Partners provided financing to support the add-on acquisition; Suttons Creek will operate as a division of ToxStrategies and its founder Steven Badelt will continue to lead the business. Terms were not disclosed.

Renovus-Backed BlueRidge Life Sciences Formed by Uniting Suttons Creek, Modality Solutions, CLINTREX and ToxStrategies

August 25, 2025

Healthcare Services

Four life-sciences consulting firms — Suttons Creek, Modality Solutions, CLINTREX, and ToxStrategies — have been unified under the new brand BlueRidge Life Sciences to create an integrated life-sciences services platform. The move, backed by private equity sponsor Renovus Capital Partners, consolidates toxicology, regulatory science, engineering, clinical research and related capabilities to offer end-to-end scientific and regulatory support to pharmaceutical, biotech, medical device and consumer-product clients.

ToxStrategies (Renovus-backed) Acquires Modality Solutions

August 8, 2023

Healthcare Services

ToxStrategies, a Renovus Capital Partners-backed life sciences consulting platform, has acquired Modality Solutions, a Houston-based firm specializing in biopharmaceutical cold-chain optimization and shipping validation testing. The add-on expands ToxStrategies' cold-chain, package engineering, and regulatory testing capabilities and will operate as a division of ToxStrategies with Modality's founders continuing to lead the business.

Labcorp Acquires Toxikon Corporation

November 18, 2021

Healthcare Services

Labcorp has acquired Toxikon Corporation, a Bedford, Massachusetts-based contract research organization that provides nonclinical in vivo and in vitro testing for pharmaceutical, biotech and medical device clients. The acquisition expands Labcorp Drug Development's nonclinical testing capabilities and creates a strategic Boston-area footprint; Toxikon reported approximately $40 million in annual revenue and the deal closed in December 2021.

Altasciences Acquires Sinclair Research

January 4, 2022

Healthcare Services

Altasciences completed the acquisition of Sinclair Research, a Midwest-based preclinical CRO, expanding its U.S. preclinical footprint and adding capacity and toxicology expertise. The deal brings Sinclair’s over-80-animal-room capabilities into Altasciences’ integrated CRO/CDMO platform to better support biopharmaceutical, animal health, and medical device development programs.